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(EQ-5D and the condition speciﬁ c Dermatitis-Life-Quality-Index (DLQI)), direct and 
indirect costs, from the societal perspective. RESULTS: A preliminary sample of 305 
patients (mean age + SD = 41.4 + 14.9, 38.2% male) were enrolled. Two hundred 
ﬁ fty ﬁ ve patients (83.6%) had CHE and of these the 27.8% were severe. Overall, 
20.0% of the enrolled patients were chronic, severe and refractory to therapy. DLQI 
mean + SD sum score was 10.38 + 5.98. With EQ-5D 92.7% of patients reported 
moderate or severe pain/discomfort, 70.9% problems with usual activities, 58.2% 
anxiety/depression and 40% problems with self-care. VAS mean + SD = 61.96 + 21.48. 
On average hospitalization cost c87.90/patient-month, travels due to CHE cost 
c69.54/patient-month, specialist visit costs c52.81/patient-month, other products 
(gloves, gauze bandage, vacuum cleaner, cosmetics) costs c35.70/patient-month, diag-
nostic exam costs c20.77/patient-month, non pharmacological therapy (emollients, 
galenic products, soap, UV-ray) cost c15.65/patient-month and pharmacological 
therapy cost c9.22/patient-month. Patients lost a mean + SD 4.35 + 8.68 workdays/
patient-month for reasons attributable to their condition. CONCLUSIONS: most of 
the patients in the Italian centers of dermatology have CHE and a ﬁ fth are severe and 
refractory to therapy. Patients with severe CHE and refractoriness to therapy have 
poor HRQoL and high costs. a correct diagnosis and treatment is necessary to efﬁ -
ciently manage this condition.
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OBJECTIVES: It is assumed broadly that the costs caused by chronic hand eczema 
(CHE) are signiﬁ cant. However, there is a lack of cost-of-illness studies on CHE. The 
objective of this study is, therefore, to determine the direct and indirect costs of chronic 
hand eczema under routine conditions overall and in different treatment stages in 
Germany. METHODS: The survey was conducted in 24 outpatient practices and 
clinics across Germany. Patients with CHE refractory to potent topical treatments and 
insured by statutory health insurances were eligible. Patient characteristics and 
resource use were directly gathered from patients and physicians. Costs were evaluated 
from the societal perspective. Four treatment stages were deﬁ ned: only topical treat-
ments (stage I), additionally photo therapy (II), systemic therapy (III) and inpatient 
treatment (IV). Bivariate associations between costs and treatment stage were assessed. 
RESULTS: A total of 223 CHE patients enrolled in the study. The yearly direct and 
indirect costs per patient are c1742 (SE: c139) and c386 (c83), respectively. a total 
of 63.2% of patients were treated only with topical treatments; additionally 15.7% 
with photo therapy, 11.7% with systemic treatments. a total 9.4% of all patients were 
admitted to hospitals. The total costs increase with treatment stage I-IV (P < 0.001): 
c1044 (c85), c2307 (c145), c2697 (c461) and c8407 (c991), respectively. Accord-
ingly, costs also correlated with clinical severity. CONCLUSIONS: CHE patients 
refractory to topical steroids incur marked costs to the society. The costs are increasing 
disproportionately with escalating treatment stages, especially in patients admitted to 
hospitals. Hence, new and innovative treatments may help to reduce the societal costs 
of CHE.
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OBJECTIVES: The objective of this analysis was to estimate the total budget dedicated 
to glaucoma care according to the UKGPRD and to identify factors associated with 
high costs. METHODS: Data were extracted on patients treated on the National 
Health Service with a diagnosis of ocular hypertension or glaucoma, or treated with 
topical intraocular lowering treatment, surgery or laser for glaucoma. The budget was 
estimated from resources consumed in 2008 and included glaucoma drugs, laser, 
surgery, hospitalization, specialist and general practitioner (GP) visits. In-patient 
resources were estimated from the Hospital Episode Statistics. Results were expressed 
in GBP, 2008. Factors associated with high cost were identiﬁ ed using linear stepwise 
regression. National extrapolation was performed according to the relative size of the 
GPRD to the UK general populations. RESULTS: Details of 33,441 patients were 
extracted, which suggests that about 510,000 patients were treated in the NHS in UK 
in 2008. The Mean age was 74.2 years, and 47.3% were male. The initial diagnosis 
was made at 67.8 years. Older patients, longer time since diagnosis, a higher number 
of previous treatments, a higher number of treatment switches in the previous one 
year period and use of laser/surgery were associated with a higher annual cost. Spend-
ing varied little between regions. Annual drug spending was £91.2 million on in-
patient care, £4.4 million on drug prescription renewal (not speciﬁ c to the glaucoma 
drug). Visits to the GP cost £34.8 million and visits to the eye specialist was >£54.0 
million although the latter ﬁ gure is likely to be an under estimate (GPRD underre-
ported eye doctor care). CONCLUSIONS: The 2008 expenditures to care for glau-
coma were >£185 million with no regional differences. Three factors were strongly 
associated with high costs: time since diagnosis, treatment changes, and rescue treat-
ment. This analysis suggests that longer treatment persistence is likely to be associated 
with cost saving.
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OBJECTIVES: Published cost-of-illness studies of psoriasis in Sweden are not avail-
able. This study estimates the societal cost of psoriasis care in a deﬁ ned Swedish patient 
population. METHODS: A prevalence-based prospective recruitment of patients visit-
ing two dermatology clinics in Sweden between September and December 2009 was 
performed. Patients collected resource utilization of health care contacts, treatment, 
travelling distance and time, and productivity loss (human capital approach) during 
1 month (Swedish unit prices, 2009). RESULTS: A total of 164 patients (49% males) 
were included; average age 52, 76% plaque psoriasis with PASI 5.7, DLQI 7.7 and 
EQ-5D utility weight 0.71. The mean total cost per patient-month was c994. Main 
cost drivers were outpatient visits (OP) and light therapy (49%), biological drugs 
(20%) and productivity loss (22%). When patients were stratiﬁ ed according to treat-
ment strategy, total costs (fraction of patients) for topical treatment only (TT; 34%) 
was c369, light therapy (LT; 24%) c1274, traditional systemic treatment (TST; 26%) 
c1085 and biological systemic treatment (BST; 16%) c1709 per patient-month. Main 
cost drivers in each treatment strategy were: OP (56%) in TT, OP (78%) in LT, 
productivity loss (40%) in TST and biological drugs (71%) in BST. There was no 
clear relationship between clinical (PASI) or subjective (DLQI) severity estimations 
and costs. CONCLUSIONS: In this study the cost-of-illness for a psoriasis patient 
amounts to almost c1000/month, with great variation depending on treatment strat-
egy. Despite the 1200 difference in drug cost for TST vs. BST, total cost per month 
differed by c600 because of offsets from improved productivity and reductions in OP 
and topical treatment. As expected, biologically treated patients had higher costs but 
lower severity probably due to the treatment effectiveness. The relationship between 
costs and severity is complex, probably due to the selected study period and differences 
in effect between strategies.
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OBJECTIVES: Wet macular degeneration associated with age (wet-AMD) is the 
leading cause of legal blindness in Spain in people over 55. The aim of this study is 
to determine health care resource utilization and mean costs per patient with wet-AMD 
in 2009. METHODS: A micro-costing analyses was performed to estimate direct 
medical costs of patients with wet-AMD. Patient level data was obtained from differ-
ent public hospitals in Spain and ophthalmologists were surveyed with a semi-struc-
tured questionnaire to obtain treatment patterns. Inpatient costs were considered from 
the perspective of the public health care system. Treatments under study were pegap-
tanib, verteporﬁ n, ramibizumab and bavacizumab. Although bevacizumab in Spain is 
not approved for wet-AMD, it was used off-label in the hospital. Direct medical costs 
considered were drug costs, administration cost, doctors’ visits, nurse time, ophthal-
mologist time, anaesthetics, ambulant hospital care, external consultation, surgery and 
treatment of adverse effects. All costs are referred to 2009. RESULTS: Mean cost per 
patient treated with wet-AMD represented the following cost for the public health 
care system: c7290 for pegaptanib, c5810c for verteporﬁ n, c8650 for ramibizumab 
and c3110 for bevacizumab. We also estimated that in Spain 180,000 people over 50 
years have wet-AMD in 2009. CONCLUSIONS: Pharmacological treatments for 
wet-AMD are photo dynamic therapy with verteporﬁ n, pegaptanib, verteporﬁ n and 
ramibizumab, with the last one having the highest medical costs. The aging of the 
population and development of new drugs will probably increase the future economic 
impact of AMD, which remains a major health care burden.
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OBJECTIVES: To describe total costs and factors predicting cost in Germany for 
glaucoma disease states: ocular hypertension (OHT), and early (EARLY), moderate 
(MOD) and advanced (ADV) glaucoma. METHODS: A 5-year retrospective analysis 
collected health care utilization, clinical parameters, treatment(s) used and reasons for 
treatment change. Disease states deﬁ ned by the European Glaucoma Society were 
applied. Costs for health care resources were based upon the German EBM/OPS code 
for ambulatory visits/procedures, diagnosis-related groups for hospital procedures and 
the Rote Liste for medication. Factors predicting cost were identiﬁ ed using stepwise 
backward multiple linear regression, entry criterion a = 0.2. RESULTS: A total of 154 
patients (27 OHT, 43 EARLY, 35 MOD, 49 ADV) were enrolled from 15 centers 
across 5 German regions. Average age was 67 ± 11 and 57% were female. Number 
of years since diagnosis was 9.0 ± 5.7, 8.7 ± 4.6, 8.7 ± 4.1 and 13.2 ± 8.3 years for 
OHT, EARLY, MOD and ADV, respectively. Total costs, for patients with OHT, 
EARLY, MOD or ADV, were c226 ± 117, c423 ± 647, c493 ± 385, and c808 ± 877, 
respectively. Most costs were due to medication (c121 ± 99, c217 ± 150, c245 ± 161, 
c340 ± 193) and hospital interventions (c32 ± 101, c115 ± 538, c154 ± 285, c367 ± 
